A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
Roche reins in the TIGIT expectations
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
